BERKELEY, Calif.--(BUSINESS WIRE)--Sept. 6, 2006--XOMA Ltd (Nasdaq:XOMA) announced today that the European Commission has granted an orphan medicinal product designation to XOMA’s drug NEUPREX(R) (opebacan) in meningococcal disease, a potentially life-threatening bacterial infection predominantly affecting young children. XOMA is currently completing the regulatory assessment for NEUPREX(R) under the European Medicines Agency’s (EMEA) exceptional circumstances mechanism and plans to base its application on existing phase III clinical trial data for NEUPREX(R).
